Navigating SCAN Health Plan Trelegy Prior Authorization

The Operational Imperative for Trelegy Prior Authorization

Trelegy Ellipta, a triple-combination inhaled corticosteroid, long-acting beta2-agonist, and long-acting muscarinic antagonist (ICS/LABA/LAMA), is a high-cost therapy for COPD and asthma. Payers like SCAN Health Plan implement prior authorization requirements to ensure medical necessity, appropriate utilization, and adherence to formulary guidelines. For revenue cycle and prior authorization teams, this translates into a mandatory verification step that must be completed accurately and promptly before dispensing.

Understanding SCAN Health Plan's PA Framework for Pharmaceuticals

SCAN Health Plan, like other Medicare Advantage and commercial plans, establishes specific medical policies and formularies that dictate prior authorization requirements. These policies often align with evidence-based criteria from sources like MCG Health or InterQual, or their own proprietary guidelines. For respiratory medications, criteria typically focus on confirmed diagnosis (e.g., ICD-10 codes for COPD or asthma), documented severity, and history of failed trials with preferred or step-therapy alternatives. Accessing the most current SCAN Health Plan formulary and medical policies is the first critical step for any Trelegy submission.

Essential Documentation for Trelegy PA Submissions

Accurate and complete documentation is paramount for securing a Trelegy prior authorization. Incomplete submissions are a primary cause of delays and denials. Prior authorization coordinators must compile a comprehensive packet that clearly justifies the medical necessity of Trelegy for the specific patient. This often requires coordination with prescribing clinicians to gather all relevant clinical data.

Key Documentation Requirements Typically Include:

• Current ICD-10 diagnosis codes supporting COPD (J44.9) or asthma (J45.909, etc.).
• Detailed clinical notes from the prescribing provider, including patient history, physical exam findings, and current symptoms.
• Documentation of spirometry or other pulmonary function tests confirming diagnosis and severity.
• A comprehensive list of previously tried and failed alternative therapies, demonstrating compliance with step therapy protocols.
• Information on contraindications or intolerances to alternative medications.
• The specific Trelegy dosage and frequency requested.
• Prescriber's National Provider Identifier (NPI) and DEA number.

Leveraging Electronic Prior Authorization (ePA) Pathways

Submitting Trelegy prior authorizations electronically significantly reduces administrative burden and turnaround times. Platforms like CoverMyMeds, Surescripts, and Availity facilitate ePA submissions, often integrating directly with EHR systems such as Epic Hyperspace or Cerner PowerChart. These systems typically utilize industry standards like NCPDP SCRIPT for pharmacy benefits or X12 278 (HIPAA) for medical benefits, streamlining data exchange between providers and payers. Implementing SMART on FHIR applications or Da Vinci PAS accelerators can further enhance data interoperability, reducing manual data entry and improving accuracy.

Common Reasons for Trelegy PA Denials and Mitigation

Despite diligent efforts, Trelegy prior authorization requests can face denials. Common reasons include insufficient documentation, failure to meet step therapy requirements, lack of demonstrated medical necessity, or a perceived lack of adherence to SCAN Health Plan's specific formulary criteria. To mitigate denials, teams must ensure all clinical criteria are explicitly addressed in the submission, and that the documentation clearly supports the prescribed therapy. Proactive communication with the prescribing clinician regarding payer requirements is also essential.

The Appeals Process and Peer-to-Peer Reviews

When a Trelegy prior authorization is denied, initiating an appeal is the next critical step. The appeals process typically involves submitting additional clinical information or clarifying the medical necessity of the treatment. For complex cases, a peer-to-peer (P2P) review may be requested. During a P2P, the prescribing clinician directly discusses the patient's case with a SCAN Health Plan medical director, providing an opportunity to present nuanced clinical details that may not be fully captured in written documentation. This direct clinical discussion can often overturn initial denials.

Optimizing PA Workflows for Respiratory Medications

Efficient management of Trelegy and other respiratory medication prior authorizations requires optimized internal workflows. This includes establishing clear roles and responsibilities within the prior authorization team, implementing robust tracking systems, and integrating ePA solutions directly into the EHR. Regular training on payer-specific requirements and updates to medical policies ensures that the team remains current. Continuous process improvement, informed by denial analytics, can significantly enhance approval rates and reduce administrative overhead.